Comparative analysis of long-term outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiology by Ozieranski, Krzysztof et al.
Cardiovascular Drugs and Therapy. 2019; 33(1): 77-86 
Comparative analysis of long-term outcomes of torasemide 
and furosemide in heart failure patients in heart failure 





















, Maria G. Crespo-Leiro
2





, Krzysztof J. Filipiak1, Grzegorz Opolski
1
 
1 Department of Cardiology, Public Central Teaching Hospital in Warsaw, Medical University of Warsaw, 1a 
Banacha St., 02-097 Warsaw, Poland 
2 Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruna, 
CIBERCV, La Coruna, Spain 
3 ANMCO Research Centre, Florence, Italy  
4 EURObservational Research Programme, European Society of Cardiology, Sophia Antipolis, France 
5 Department of Cardiology, Cardiology and Cardiac Surgery, Medical University of Lodz, Lodz, Poland 
Abstract 
Purpose. Current clinical recommendations do not emphasise superiority of any of diuretics, but available 
reports are very encouraging and suggest beneficial effects of torasemide. This study aimed to compare the 
effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class 
change in patients with chronic heart failure (HF). 
Methods. Of 2019 patients enrolled in Polish parts of the heart failure registries of the European Society of 
Cardiology (Pilot and Long-Term), 1440 patients treated with a loop diuretic were included in the analysis. 
The main analysis was performed on matched cohorts of HF patients treated with furosemide and torasemide 
using propensity score matching. 
Results. Torasemide was associated with a similar primary endpoint (all-cause death; 9.8% vs. 14.1%; 
p = 0.13) occurrence and 23.8% risk reduction of the secondary endpoint (a composite of all-cause death or 
hospitalisation for worsening HF; 26.4% vs. 34.7%; p = 0.04). Treatment with both torasemide and 
furosemide was associated with the significantly most frequent occurrence of the primary (23.8%) and 
secondary (59.2%) endpoints. In the matched cohort after 12 months, NYHA class was higher in the 
furosemide group (p = 0.04), while furosemide use was associated with a higher risk (20.0% vs. 12.9%; 
p = 0.03) of worsening ≥ 1 NYHA class. Torasemide use impacted positively upon the primary endpoint 
occurrence, especially in younger patients (aged < 65 years) and with dilated cardiomyopathy. 
Conclusions. Our findings contribute to the body of research on the optimal diuretic choice. Torasemide may 
have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger 
patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised 
trials. 
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Introduction 
Approximately 50% of heart failure (HF) patients are readmitted to hospital within 6 months 
due to HF deterioration, which indicates that symptomatic treatment of HF requires significant 
improvement [1]. HF-related readmissions can be reduced by proper management of fluid 
retention [2]. As demonstrated by recent European registries, diuretics are prescribed in 
approximately 83% of patients with chronic HF at hospital discharge and ambulatory care [3, 4]. 
Current recommendations do not emphasize the superiority of any of the available diuretics [1]. 
Furosemide is the most commonly used loop diuretic, yet it is known that as a non-potassium-
sparing diuretic (PSD), it activates aldosterone secretion. It was shown in a retrospective analysis 
of Studies Of Left Ventricular Dysfunction (SOLVD), that it may lead to negative outcomes (HF 
hospitalization, death from cardiovascular or all-causes) compared to PSD alone or combined 
therapy [5]. Emerging evidence is encouraging, suggesting a range of beneficial effects of 
torasemide. Several small studies suggested a potential decrease in mortality and hospitalizations 
for worsening HF [6, 7]. Further, in TORasemide In Chronic Heart Failure (TORIC) study, 
torasemide was related with lower mortality and was more efficacious than furosemide in 
improving New York Heart Association (NYHA) functional class [6]. Additionally, torasemide 
has been shown to have a favourable effect on the renin-angiotensin-aldosterone system (RAAS) 
[8]. In patients with chronic HF, torasemide attenuated cardiac fibrosis and left ventricular 
remodelling [9, 10]. That being said, given the frequent deteriorations of HF, there is a clear need 
for further research comparing torasemide with furosemide, both in randomised trials, as well as in 
real-life patients in an everyday practice. 
 
Our study sought to compare the effect of torasemide and furosemide on long-term outcomes 
and NYHA functional class change in patients with chronic HF, enrolled in Polish parts of the 
heart failure registries of the European Society of Cardiology (ESC)—Pilot and Long-Term. 
Methods 
Study Design 
The study consisted of the Polish data from two prospective, observational ESC-HF 
registries—Pilot and Long-Term. The Pilot study, lasting from October 2009 to May 2010, 
enrolled patients in 136 European cardiology centres (29 from Poland). The Long-Term registry 
was conducted in 211 centres from 21 European countries, from May 2011 to April 2013. Patients 
were enrolled on a 1 day per week basis for 12 consecutive months. A list of the participating 
centres has been previously published [11, 12]. The surveys were approved by a local ethical 
review board. 
 
Registries included outpatients and inpatients with chronic, worsening or new-onset HF. The 
studies enrolled patients who were over 18 years of age, met diagnostic criteria for HF and 
provided informed written consent. There were no specific exclusion criteria. Investigators 
gathered data regarding medical history, demographics, clinical status, diagnostic tests result, 
pharmacotherapy and 1-year observation. 
 
The total daily dose of loop diuretics was assessed for each patient. According to the 
manufacturer’s recommendations, 40 mg of furosemide corresponds with 10 mg of torasemide. In 
order to unify the doses of loop diuretics for analysis, the following four levels of doses of 
furosemide were established: dose 1, ≤ 40 mg; dose 2, > 40–80 mg; dose 3, > 80–120 mg; and dose 
4, > 120 mg, which corresponded with the following doses of torasemide: dose 1, ≤ 10 mg; dose 2, 
> 10–20 mg; dose 3, > 20–30 mg; and dose 4, > 30 mg. A comparison of similar doses was 
performed by Eshaghian et al. [13]. 
  
Study Population and Group Selection 
In the registries ESC-HF Pilot and ESC-HF Long-Term, 5118 and 12,440 patients across 
Europe were enrolled, respectively. The total Polish cohort of the registry consisted of 2019 
Caucasian patients, including 1415 inpatients and 604 outpatients. The final analysis included 
1440 inpatients who survived and were discharged in a stable condition, as well as ambulatory 
patients with chronic HF. Among those 1440 patients, 986, 319 and 135 patients had prescribed 
furosemide, torasemide or both furosemide and torasemide, respectively. Death (analysed only in 
hospitalised patients) and lack of loop diuretic were the reasons for exclusion in 579 subjects. 
Figure 1 shows the flow chart of patient enrollment in the study. Data on 1-year survival, 1-year 
survival or readmission for decompensated HF, and NYHA functional class change were available 




Fig. 1 Flow chart of patient enrollment in the study 
Comparative Analysis of Patients Treated with Loop Diuretics 
Investigators assessed the frequency of usage of loop diuretics and baseline characteristics 
(discharge data in case of hospitalised patients) of patients treated with furosemide and torasemide. 
The main analysis was performed on matched groups of HF patients treated with furosemide and 
torasemide using propensity score matching. Matched cohorts were compared with regard to the 
occurrence of primary endpoint (all-cause death at 1 year), secondary endpoint (a composite of all-
cause death or hospitalisation for worsening HF at 1 year) and changes in NYHA functional class 
from baseline to the end of 12-month follow-up. Additionally, 1-year outcomes and NYHA 




For the comparison of the groups’ characteristics, the Fisher exact test and Mann-Whitney U 
test were performed for categorical and continuous variables, respectively. Propensity scores for 
treatment with torasemide or furosemide were estimated for each patient with logistic regression 
using four clinically relevant baseline variables (age, gender, NYHA functional class, diuretic 
dose), which were consistent with variables used by investigators of the TORIC study [6]. The 
propensity score is the propensity from 0 to 1 to receive a treatment. It is used in observational 
studies to attempt to adjust for potential selection bias, confounding and differences between 
treatment groups [14, 15]. Matching was 1:1 and without replacement. Each patient with 
torasemide was matched to the closest patient with furosemide. This yielded 319 patients in each 
group. Kaplan-Meier curves were plotted for the primary and the secondary endpoints. Interactions 
between torasemide or furosemide use and all baseline variables in the matched cohort were 
estimated by Cox regression analysis and displayed in a forest plot. All tests were two tailed, and a 
p value less than 0.05 was considered significant. Statistical analyses were performed using SPSS 
software, version 22 (IBM SPSS Statistics 22, New York, USA). 
Results 
Baseline Characteristics 
Before matching, there were significant differences between treatment groups. Patients in the 
furosemide group had a worse clinical condition manifested by lower ejection fraction, higher 
resting heart rate, lower systolic blood pressure, higher serum creatinine level and lower 
haemoglobin concentration, and therefore, they required a higher diuretic dose than patients in the 
torasemide group. Moreover, they more frequently received oral anticoagulation and less 
frequently beta-blockers than patients treated with torasemide. After matching, the furosemide and 
torasemide groups differed only in a higher incidence of stroke history in the torasemide group. 
Baseline characteristics of both groups, regarding medical history, clinical status and 
pharmacotherapy, are presented in Table 1. 
Table 1 Baseline characteristics of the overall and matched cohorts of patients in the furosemide and torasemide groups 
Variable 
Overall cohort  Matched cohort 














 Age, years 66 (58–77); n = 135 67 (58–77); n = 986 67 (58–77); n = 319 0.89* and 0.81**  68 (59–77); n = 319 67 (58–77); n = 319 0.60 
 Male 72.6%; 98/135 70.7%; 697/986 69.6%; 222/319 0.72* and 0.86**  69.6%; 222/319 69.6%; 222/319 1.00 
 BMI, kg/m2 28.0 (25.0–31.3); n = 135 28.0 (24.9–31.0); n = 981 27.0 (25.0–32.0); n = 319 0.71* and 0.15**  28.0 (25.0–31.7); n = 319 27.0 (25.0–32.0); n = 319 0.71 
HF 
 LVEF, % 29 (20–40); n = 131 32 (24–45); n = 913 35 (25–50); n = 309 0.01* and < 0.001**  35 (25–46); n = 299 35 (25–50); n = 309 0.30 
 Diuretic dose*** 3 (2–4); n = 135 1 (1–2); n = 986 1 (1–1); n = 319 < 0.0001* and 
< 0.0001* 
 1 (1–1); n = 319 1 (1–1); n = 319 0.19 
 Ischaemic heart disease 43.7%; 59/135 53.7%; 529/986 52.2%; 166/318 0.65* and 0.06**  57.4%; 183/319 52.2%; 166/318 0.20 
 Dilated cardiomyopathy 28.9%; 39/135 18.5%; 182/986 19.1%; 61/319 0.80* and 0.02**  17.2%; 55/319 19.1%; 61/319 0.61 
 Valve disease 15.6%; 21/135 12.1%; 119/986 11.6%; 37/319 0.69* and 0.51**  11.6%; 35/319 11.6%; 37/319 0.90 
Medical history 
 AF 54.1%; 73/135 47.2%; 464/984 41.4%; 132/319 0.08* and 0.75**  44.5%; 142/319 41.4%; 132/319 0.47 
 CAD 54.1%; 73/135 51.9%; 511/985 55.8%; 178/319 0.25* and 0.33**  54.2%; 173/319 55.8%; 178/319 0.75 
 History of PCI or CABG 40.1%; 54/135 38.1%; 375/985 38.6%; 123/319 0.90* and 0.51**  40.1%; 128/319 38.6%; 123/319 0.75 
 Hypertension 65.9%; 89/135 61.3%; 603/984 67.0%; 213/318 0.07* and 0.09**  63.8%; 203/318 67.0%; 213/318 0.45 
 PAD 12.6%; 17/135 13.2%; 130/986 11.0%; 35/317 0.33* and 0.52**  15.0%; 48/319 11.0%; 35/317 0.16 
 Diabetes 40.7%; 55/135 36.6%; 361/986 30.7%; 98/319 0.06* and 0.85**  36.1%; 115/319 30.7%; 98/319 0.18 
 CKD 37.8%; 51/135 20.8%; 205/984 21.0%; 67/319 0.94* and < 0.001**  19.1%; 61/319 21.0%; 67/319 0.62 
 COPD 24.4%; 33/135 20.0%; 197/985 15.7%; 50/319 0.10* and 0.89**  20.4%; 65/319 15.7%; 50/319 0.15 
 Stroke 11.9%; 16/135 10.6%; 104/984 12.9%; 41/319 0.26* and 0.37**  7.2%; 23/319 12.9%; 41/319 0.02  
 Pacemaker 6.7%; 9/135 7.6%; 75/986 5.3%; 17/319 0.21* and 0.32**  7.8%; 25/319 5.3%; 17/319 0.26 
 ICD 22.2%; 30/135 17.3%; 270/985 14.4%; 46/319 0.19* and 0.57**  15.7%; 50/319 14.4%; 46/319 0.65 
 CRT 8.1%; 11/135 6.5%; 64/985 6.6%; 21/319 1.00* and 0.55**  6.6%; 21/319 6.5%; 64/985 0.92 
 Smoking† 55.6%; 75/135 58.1%; 561/966 60.5%; 193/319 0.47* and 0.94**  56.4%; 177/314 60.5%; 193/319 0.30 
Clinical status 
 NYHA class 3 (2–3); n = 134 2 (2–3); n = 983 2 (2–3); n = 319 0.79* and < 0.001**  2 (2–3); n = 319 2 (2–3); n = 319 0.26 
 SBP, mmHg 120 (100–130); n = 135 125 (110–140); n = 984 130 (115–140); n = 319 0.049* and < 0.001**  126 (110–140); n = 319 130 (115–140); n = 319 0.25 
 DBP, mmHg 70 (65–80); n = 135 80 (70–81); n = 983 80 (70–86); n = 319 0.13* and 0.002**  80 (70–80); n = 319 80 (70–86); n = 319 0.23 
 Heart rate, bpm 80 (70–100); n = 135 80 (70–96); n = 983 75 (66–90); n = 319 0.004* and 0.049**  80 (68–95); n = 318 75 (66–90); n = 319 0.17 
Laboratory findings 
Table 1 Baseline characteristics of the overall and matched cohorts of patients in the furosemide and torasemide groups 
Variable 
Overall cohort  Matched cohort 












 Serum sodium, mmol/l 138 (135–141); n = 125 139 (136–141); n = 921 139 (137–141); n = 300 0.20* and 0.04**  139 (136–141); n = 303 139 (137–141); n = 300 0.45 
 Serum potassium, mmol/l 4.5 (4.0–4.8); n = 124 4.4 (4.1–4.8); n = 923 4.4 (4.1–4.8); n = 305 0.74* and 0.99**  4.43 (4.1–4.8); n = 305 4.41 (4.1–4.8); n = 305 0.98 
 Serum creatinine, mg/dl 1.36 (1.09–1.91); n = 125 1.16 (0.93–1.54); n = 914 1.10 (0.88–1.34); n = 306 0.001* and 0.31**  1.11 (0.94–1.45) n = 300 1.10 (0.88–1.34); n = 306 0.15 
 Haemoglobin, g/dl 13.3 (12.0–14.5); n = 122 13.3 (12.0–14.5); n = 904 13.7 (12.2–14.8); n = 297 0.03* and 0.08**  13.6 (12.2–14.7); n = 303 13.7 (12.2–14.8); n = 297 0.64 
Pharmacotherapy 
 ACEIs 74.1%; 100/135 80.5%; 794/986 80.9%; 258/319 0.94* and 0.19**  80.3%; 256/319 80.9%; 258/319 0.92 
 ARBs 11.1%; 15/135 12.9%; 127/985 13.2%; 42/319 0.92* and 0.69**  14.7%; 47/319 13.2%; 42/319 0.65 
 Beta-blockers 88.1%; 119/135 91.4%; 901/986 95.3%; 304/319 0.02* and 0.02**  94.0%; 300/319 95.3%; 304/319 0.60 
 Aldosterone antagonists 77.8%; 105/135 70.2%; 692/986 70.2%; 224/319 1.00* and 0.15**  68.7%; 219/319 70.2%; 224/319 0.73 
 CCBs 8.1%; 11/135 12.0%; 118/986 13.5%; 43/319 0.49* and 0.51**  16.0%; 51/319 13.5%; 43/319 0.43 
 Statins 57.0%; 77/135 66.6%; 657/986 68.3%; 218/319 0.58* and 0.14**  66.5%; 212/319 68.3%; 218/319 0.67 
 Amiodarone 17.0%; 23/135 10.5%; 104/986 11.3%; 36/319 0.76* and 0.06**  7.8%; 25/319 11.3%; 36/319 0.18 
 Other antiarrhythmics 6.7%; 9/135 6.0%; 59/986 5.6%; 18/319 0.89* and 0.89**  5.3%; 17/319 5.6%; 18/319 1.00 
 Digoxin 34.1%; 46/135 30.0%; 296/986 26.0%; 83/319 0.18* and 0.92**  25.7%; 82/319 26.0%; 83/319 1.00 
 OAC 57.8%; 78/135 47.3%; 466/985 38.6%; 123/319 0.01* and 0.001**  43.9%; 140/319 38.6%; 123/319 0.20 
 Antiplatelets 51.1%; 69/135 58.5%; 577/986 62.7%; 200/319 0.19* and 0.51**  63.0%; 201/319 62.7%; 200/319 1.00 
 
 
Values in italics indicate p values < 0.05 
ACEIs angiotensin-converting enzyme inhibitors, AF atrial fibrillation, ARBs angiotensin receptor blockers, BMI body mass index, CABG coronary artery bypass grafting, CAD coronary artery disease, CCBs 
calcium channel blockers, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CRT cardiac resynchronization therapy, DBP diastolic blood pressure, HF heart failure, ICD implantable 
cardioverter defibrillator, LVEF left ventricular ejection fraction, NYHA New York Heart Association, OAC oral anticoagulant, PAD peripheral artery disease, PCI percutaneous coronary intervention, SBP 
systolic blood pressure 
*p value for comparison of torasemide versus furosemide groups 
**p value for any trend between groups 
***Diuretic dose was established as levels from 1 to 4. A detailed explanation is mentioned in the “Methods” section 
†Current or former 
 
Of the 319 patients treated with torasemide, 25 patients (7.8%) received additional diuretics 
(hydrochlorothiazide, chlorthalidone or indapamide), while in the furosemide group (consisting of 
986 patients), 89 patients (9.0%) were treated with additional diuretics. 
 
In the matched cohort, the doses of the loop diuretics were as follows: dose 1 (272 patients of 
the torasemide group vs. 259 patients of the furosemide group), dose 2 (32 vs. 44, respectively), 
dose 3 (6 vs. 8, respectively) and dose 4 (9 vs. 8, respectively). 
Primary and Secondary Endpoints 
Overall Cohort 
The primary endpoint in the unmatched cohorts was reached in 13.1%, 9.8% and 23.8% (p 
value of 0.01 for any trend) of patients in the furosemide, torasemide and both furosemide and 
torasemide groups, respectively. The secondary endpoint occurred in 37.2%, 26.4% and 59.2% (p 
value < 0.0001 for any trend) of patients in the furosemide, torasemide and both furosemide and 
torasemide groups, respectively. 
Matched Cohort 
In the matched cohort, the torasemide group was found to have a 30.2% reduction in the risk of 
death compared to the furosemide group, but it was not statistically significant (p = 0.13) (Table 
2). A total of 30 (9.8%) patients in the torasemide group and 43 (14.1%) patients in the furosemide 
group died during the study. In the matched cohort, in the torasemide-treated patients, there was a 
23.8% risk reduction of the secondary endpoint (p = 0.04). During the 1-year follow-up, death or 
hospitalisation for worsening HF occurred in a total of 74 (26.4%) patients in the torasemide group 
and 95 (34.7%) patients in the furosemide group. Kaplan-Meier curves for the primary and 
secondary endpoints are plotted in Fig. 2. 
Table 2 Incidence of the primary and secondary endpoints, and NYHA functional class at 1 year in patients who received 
torasemide, furosemide or both furosemide and torasemide (in the matched and not matched cohorts) 
  








p value*  
Furosemide group 
(n = 319) 
p 
value** 
        
Death 23.8%; 31/130 13.1%; 124/946 9.8%; 30/305 0.01   14.1%; 43/305 0.13 
Death or 
hospitalisation 
59.2%; 74/125 37.2%; 316/850 26.4%; 74/280 < 0.0001   34.7%; 95/274 0.04  
NYHA class at 
12 months 
3 (2–3); n = 101 2 (2–3); n = 886 2 (2–2); n = 262 0.001   2 (2–3); n = 254 0.04  
        
 
Values in italics indicate p values < 0.05 
*p value for any trend between groups in the not matched cohorts 





Fig. 2 Kaplan-Meier curves for the primary (a) and secondary (b) endpoints in matched cohorts treated with furosemide or 
torasemide, and both furosemide and torasemide 
Treatment with both torasemide and furosemide was associated with the most frequent 
occurrence of the primary (23.8%) and secondary (59.2%) endpoints (Table 2). The results were 
statistically significant. 
Change in NYHA Class 
Overall Cohort 
In the unmatched cohorts, the median NYHA class at 12 months was as follows: 2 (2–3), 2 (2–
2) and 3 (2–3) (p value of 0.001 for any trend) of patients in the furosemide, torasemide and both 
furosemide and torasemide groups, respectively. 
Matched Cohort 
At baseline, patients in the torasemide and furosemide groups did not differ in NYHA 
functional class, while after 12 months in the furosemide group, NYHA functional class was 
significantly higher (p = 0.04). Improvement of ≥ 1 NYHA functional class was greater in the 
torasemide group (67 patients, 25.6%) than in the furosemide group (53 patients, 20.9%) 
(p = 0.21). Furthermore, furosemide use was associated with a significantly higher risk (20.0% vs. 






Fig. 3 Changes in New York Heart Association (NYHA) functional class from baseline to the end of 12-month follow-up 
in the matched cohort 
Loop Diuretics in Subgroups of Patients with HF 
Interactions of the use of loop diuretics in the matched cohort for clinically relevant baseline 
variables are presented in Fig. 4a, b (for the primary and secondary endpoints, respectively). In 
patients treated with torasemide, a positive impact on the primary endpoint occurrence was 
observed in younger patients (aged < 65 years), with dilated cardiomyopathy, using antiplatelets or 
digitalis. A lower risk of death or hospitalisation for HF worsening was observed in patients who 
were treated with torasemide and who were 65–75 years of age, treated with angiotensin-
converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARB), statins or antiplatelets. 
In patients treated with a low dose (≤ 40 mg of furosemide or ≤ 10 mg of torasemide) of a loop 





Fig. 4 All-cause mortality (a) and mortality or hospitalization for worsening HF (b) at one-year for patients treated with 
torasemide vs treated with furosemide in the matched cohort (part 1). ACE-I - angiotensin-converting-enzyme inhibitors, 
ARB - angiotensin receptor blockers, BB – beta-blockers. Red bolded text indicates p-values <0.05. Diuretic dose was 
established as levels from 1 to 4. Detailed explanation is placed in the Methods” section 
Discussion 
The results of this observational cohort study showed that in real-life patients treated with 
torasemide, in comparison with furosemide, there were no significant differences in terms of the 
primary endpoint. However, in the torasemide-treated group, death or HF hospitalisation less 
frequently occurred. It seems that patients in the torasemide group were also more likely to have 
less HF symptoms (manifested by NYHA functional class change), thus confirming the results of 
previous studies [6, 7, 16, 17]. Nevertheless, the worse 1-year outcomes occurred in the group 
treated with both furosemide and torasemide. 
 
There is currently no consensus as to which of the loop diuretics (furosemide or torasemide) 
should be the preferred choice in HF patients. Torasemide appears to be a drug with greater 
potential, but so far, there has been insufficient research into its effects in HF therapy. The 
subanalysis of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart 
Failure (ASCEND-HF) trial demonstrated that there was a significant regional variation in the use 
of loop diuretics. Specifically, torasemide is used less frequently than furosemide in the USA 
(11.4%), China (9.4%) and Poland (6.3%) [16]. In our analysis, the most commonly used loop 
diuretic among Polish patients participating in both ESC-HF registries was furosemide (75.6% vs. 
24.4% patients treated with torasemide). These results suggest that physicians still have a stronger 
preference to prescribe furosemide than torasemide. 
  
Loop diuretics are the most efficacious drugs in relieving clinical signs and symptoms of HF 
[18]. However, there is a near consensus that diuretics do not improve the prognosis of HF patients 
and may be associated with progression of HF due their impact on RAAS activation and harmful 
effect on electrolyte concentrations [19, 20]. Even so, available data suggests that torasemide may 
offer additional advantages regarding HF hospitalizations, functional improvement, quality of life 
and even mortality, over furosemide and other diuretics [5, 6, 7]. 
 
In a randomised, open-label trial in 234 patients with chronic HF, Murray et al. [7] showed a 
significant reduction in hospitalization rates for HF and cardiovascular causes in torasemide-
treated patients, as compared to furosemide. In the TORIC study, torasemide treatment was 
associated with a significantly lower total and cardiac mortality [6]. In addition, in some studies in 
torasemide-treated patients, compared to treatment with furosemide or other diuretics, there was a 
significantly greater improvement in NYHA functional class [6, 17, 21]. Based on the available 
results of the previous and current studies, no conclusions can be drawn regarding the effect of 
diuretics on mortality. What is more, more facts speak against the effectiveness of diuretics in 
improving the primary endpoint. However, it is expected that further data will be provided by the 
recently registered ToRsemide compArisoN With furoSemide FORManagement of Heart Failure 
(TRANSFORM-HF) study, which will enroll 6000 patients hospitalised for HF in the USA, and 
which aims to compare the effects of treatment strategy based on torasemide versus furosemide on 
clinical outcomes over 12 months (ClinicalTrials.gov Identifier: NCT03296813). 
 
It remains unclear which populations of HF patients may especially benefit from treatment 
with torasemide. An analysis of the matched cohort revealed that in terms of the primary endpoint 
treatment with torasemide would especially benefit younger patients (aged < 65 years), with 
dilated cardiomyopathy and treated with antiplatelets or digitalis (Fig. 4), while the secondary 
endpoint was reduced in patients treated with torasemide and who required a low dose of a loop 
diuretic (≤ 40 mg of furosemide or ≤ 10 mg of torasemide), were treated with ACEI or ARB, 
antiplatelets or statins (Fig. 4b). These results are consistent with the study of Han et al. [22], 
showing that torasemide is advantageous in improving cardiac function by reducing arrhythmia 
and chronic HF in patients with dilated cardiomyopathy, as compared to furosemide. It has also 
been shown that HF patients not receiving ACEI/ARB or beta-blockers, a core treatment of HF, 
have a higher mortality risk [23, 24]. This effect is reflected especially with increasing doses of a 
loop diuretic, probably due to the RAAS activation by diuretics [23, 25]. 
 
In our study, the highest risk of the primary and secondary outcomes was observed in patients 
treated with both furosemide and torasemide, but those patient groups were not matched. It is 
unclear whether a worse long-term prognosis, associated with the simultaneous use of both loop 
diuretics, depends on the generally worse condition of those patients or whether it can be ascribed 
to the direct effect of application of the two diuretics. It has been shown that the risk of mortality is 
dose dependent and increases with the diuretic dose [13, 23]. Notably, the threshold value of 
50 mg of furosemide daily was identified as the strongest predictor of death within 3 years [23]. A 
similar threshold dose for torasemide has not been investigated. 
 
Torasemide has smaller inter- and intraindividual variations in bioavailability and longer 
action, reduces body weight and decreases the number of micturition at 3 h, 6 h and 12 h after 
diuretic intake and the urgency to urinate [26, 27]. Consequently, torasemide has more predictable 
pharmacokinetics/pharmacodynamics, weaker influence on electrolyte concentrations and, 
therefore, an improved tolerability compared to furosemide [28]. Vargo et al. [26] showed that in 
contrast to furosemide, the rate of absorption of orally administered torasemide was not affected in 
patients with HF. 
  
Separately, torasemide, beyond its pure diuretic effect, might also provide additional benefits 
in patients with HF. Diuretics, especially furosemide, provoke the activation of RAAS [29]. 
Contrastingly, torasemide combines the effects of diuretics, but also those of spironolactone 
(manifested by the RAAS blockade) [8]. Therefore, torasemide might attenuate myocardial 
remodelling and cardiac fibrosis [10]. Through an inhibition of aldosterone receptor, torasemide 
may also promote lesser potassium excretion than furosemide [6]. The antialdosterone action of 
torasemide may explain its ability to improve prognosis in HF patients. The TORasemide oN 
hemodynAmic and neurohormonal stress, and carDiac remOdelling in heart failure (TORNADO, 
NCT01942109), is an ongoing randomised clinical trial, may provide insight in this as it aims to 
assess the favourable effects of torasemide on biochemical and clinical parameters, and its 
effectiveness versus furosemide in improving cardiac remodelling and haemodynamic and 
neurohormonal stress in patients with HF [30]. 
 
So far, two expert groups, drawing on the available clinical reports and economic advantages, 
recommended consideration of torasemide use over furosemide in HF patients [31, 32]. It seems 
that our study supports previous reports demonstrating that treatment with torasemide might 
translate into improvement of NYHA functional class, quality of life and better prognosis of 
patients with HF, compared to furosemide, but it is just an observational study. Particular groups 
of patients which may possibly benefit from torasemide treatment are younger patients and those 
with dilated cardiomyopathy. However, there is a need for further randomised clinical trials to 
clarify this possible positive effect of torasemide. On the other hand, patients who were treated 
with both torasemide and furosemide had a worse prognosis, most likely due to a worse clinical 
condition at baseline. 
Limitations of the Study 
A limitation of the study was an insufficient number of study patients to perform a propensity 
score matching for all clinically relevant variables. For the same reason, we were not able to 
compare patients treated with both furosemide and torasemide (135 patients) with patients treated 
with torasemide or furosemide alone. To unify the doses of loop diuretics for analysis, the authors 
had to establish the four levels of doses, but it was consistent with a previously performed analysis 
[13]. The main advantage of the registries is that they include real-world patients, but they are 
associated with incompleteness of data, which could affect the results. 
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